IBC LIFE SCIENCES

5TH ANNUAL

BIOSIMILARS ASIA

2014第5届年度生物仿制药亚洲会议

Part of BIOPHARMA DEVELOPMENT & PRODUCTION WEEK

Collaborative Development and Successful Commercialization
协同发展与成功商业化

20 — 23 May 2014

Grand Hyatt Shanghai, China

上海金茂君悦大酒店, 中国

FEATURING INSIGHTS FROM:

Andrea Laslop
Head of Scientific Office, Austrian Agency for Food & Health Safety, Austrian Member, **European Medicines Agency**

Jianguo Yang
Principal Scientist, **Sanofi Genzyme,** USA

Dr Victoria Elegant
VP Medical & Regulatory Affairs, **Baxter,** China

Sameer Agarwal
Senior Vice President, Business Center Strategic Marketing, Business Unit Generic Drugs & Standard Solutions, **Fresenius Kabi Deutschland GmbH,** Germany

Jeremy Caudill
Global Vice President Business Development, **Samsung Biologics,** Korea

Dr Shaligram Rane
Vice President for Quality, **Intas Pharmaceuticals,** India

Wenzhi Tian
CEO, **Huabo Biopharma,** China

WHAT'S NEW IN 2014:

- Revamped agenda featuring insights from new speakers
- Still the most trusted biosimilars conference in Asia bringing hard-hitting discussions and insightful case studies
- Special focus on successful partnership & collaboration models
- Expanded network of biosimilars R&D thought-leaders and leading biomanufacturing players
- Interactive format including roundtables, networking cocktails, more panel discussions and speed networking for improved business deal making
- The premier meeting place for biosimilars players, investors and stakeholders in the region

2014 年的新特色:

- 修订后的议程包含新演讲嘉宾的深刻见解
- 仍然是亚洲最值得信赖的生物仿制药会议，将提供一针见血的讨论和深刻的案例研究
- 特别关注成功的伙伴关系与协作模式
- 生物仿制药研发思想领袖和领先生物制造商齐聚一堂
- 互动方式包括圆桌会议、社交鸡尾酒会、更多小组讨论和快速社交会议，便于更好地达成商业交易
- 会场位置便利，当地生物仿制药商、投资者和利益相关者将云集于此

Pre-Conference Special Focus Day, 20 May 2014
Clinical Development for Biosimilars

Post-Conference Workshops, 23 May 2014
A: Challenges in Demonstrating Biosimilarity and Interchangeability of Biosimilar Products
B: Successfully Bringing Biosimilars to Market

Produced by: ibc Life Sciences, an informa business

Sponsors: fef, a Novo Nordisk company; QUINTILES; PRA; BD

Associations: BayHelix GROUP; BIOISRAEL.COM

Media Partners: ASIA PACIFIC BIOTECH; AsianScientist; Bentham Science; BIO-EQUIP; Bioon.com; BioSpectrum; BioProcess International; BioPharm Insight; BIOSIMILAR NEWS; BIOSINGAPORE; labbase.net; GaBi; GB; GEN Genetic Engineering & Biotechnology News; KONG POSH Publications; 医药商情; lingmed; PharmaAsia; Pharma Connections; PHARMA CHINA; Technology Networks

International Marketing Partner: Global Information

Email: elizabeth.bernos@ibcasia.com.sg Tel no. +65 65082490 Fax no. +6565082406

08:00 **Registration Opens & Morning Coffee**

08:50 **Welcome Address from IBC Asia & Ice Breaker**

Exchange Business Cards & Get To Know Industry Peers

09:00 **Chairperson's Opening Remarks**

BIOPHARMA VISIONARY KEYNOTE SESSIONS

9:05 **Global Biopharma Outlook**

KEYNOTE PANEL

- Trends in the global biopharma industry
- Priorities of investment in China and opportunities for growth
- Challenges and opportunities in the Asian region
- The role of Biosimilars in the region's biopharma industry
- Key criteria to further the development of the sector in China and Asia

Moderator:
Jianguo Yang, Principal Scientist, **Sanofi Genzyme**, USA

Panelists:
Sameer Agarwal, *Senior Vice President, Business Center Strategic Marketing, Business Unit Generic Drugs & Standard Solutions*, **Fresenius Kabi Deutschland GmbH**, Germany
Abdullah Baaj, *CEO*, **Boston Oncology**, USA
Youling Wu, *CEO*, **Zhejiang Teruisi**, China
Jeremy Caudill, *Global Vice President Business Development*, **Samsung Biologics**, Korea
Scott Liu, *CEO*, **Henlius Biopharmacueticals**, China

9:50 **Biopharma Regulatory Updates and Development**

REGULATORY LEADERS PANEL

- Clinical approvals for biopharmaceuticals
- Regulatory differences between the FDA/EMA/ICH and local agencies in China and other emerging markets such as India and SEA
- How to demonstrate process consistency and what is required
- Accelerating IND applications
- Updates on Biosimilars guidelines in key Asian markets

Panelists:
Dr Victoria Elegant, *VP Medical & Regulatory Affairs*, **Baxter**, China
Andrea Laslop, *Head of Scientific Office, Austrian Agency for Food & Health Safety, Austrian Member*, **European Medicines Agency**
Dr Arvind Mishra, *Global Head of Quality & Regulatory & Head of Strategic Business Unit, Biologicals*, **Cadilla Pharmaceutical**, India

BIOPHARMA TECHNOLOGY SHOWCASE

10:30 **Cutting Edge Solutions and Innovation in Biopharma**

If you have leading edge technology and solutions and would like to showcase your innovation in front of the biopharma industry stakeholders, please contact Yvonne Leong:
Yvonne.leong@ibcasia.com.sg

11:00 **Morning Networking & Refreshment break**

ADVANCES IN BIOSIMILARS R&D

11:45 **Biosimilars Quality Development and Approval Updates**

PANEL DISCUSSION

- Ensuring the safety and efficacy of biosimilars
- Why testing for immunogenicity is important for biosimilars
- Understanding the FDA's draft guidance on biosimilarity and interchangeability
- Navigating the regulatory framework for the EU and US biosimilar approvals

Moderator:
Scott Liu, *CEO*, **Henlius Pharmacueticals**, China

Panelists:
Dr Shaligram Rane, *Vice President for Quality*, **Intas Pharmaceuticals**, India
Jeffrey Su, *CSO*, **Cytovance Biologics**, USA
Wenzhi Tian, *CEO*, **Huabo Biopharma**, China
Vivian Lee, *Associate Professor, School of Pharmacy Assistant Dean, Faculty of Medicine*, **Chinese University of Hong Kong**

12:30 **Efficiency in the Upstream Process**

- Significance of cell media in the manufacturing of biosimilars
- Importance of same quality of Insulin in growth media in biosimilars as in originators
- Function in cell growth

Francesc Gódia Casablancas, *Professor of Chemical Engineering – Tissue and Cell Engineering Group*, **Universitat Autonoma de Barcelona**, Spain

13:00 **Networking Lunch and VIP Tables**

VIP Table 1: **Dr Villoo Moralawa-Patell**, *Founder and CMD*, **Avesthagen**, India

VIP Table 2: **Yongkui Sun**, *VP, Greater China Lead, External Scientific Affairs, Worldwide Licensing and Acquisitions*, **Merck**, China

If you would like to be seated on a table with the above guests in an exclusive lunch setting, please register your interest with **elle.quan@ibcasia.com.sg**. Limited seats are available!

14:30 **China Trends, Challenges and Strategies for Biosimilar Therapeutic Antibody Development**

CXO PANEL DISCUSSION

- Where is the direction of mABs in China?
- Addressing the challenges of complex structures, tighter quality controls during production and regulatory approvals
- Learning from partnerships that led to success
- New areas of commercial opportunity for mABs

Moderator:
Ming Wang, *President & COO*, **Gan & Lee Pharmaceuticals**, China

Panelists:
Xuenming Qian, *Chairman & CEO*, **MabSpace Biosciences**, China
John Wang, *CEO & Co-founder*, **ImmunoOn Therapeutics**, China
Feng Gao, *COO*, **Autekbio**, China
Feng Li, *CEO*, **Beijing Mabworks**, China

15:15 **Challenges in Demonstrating Biosimilarity and Interchangeability of Biosimilar Products**
Rodeina Challand, *Executive Director, Biosimilars Development*, **PRA**, UK

15:45 **Afternoon Networking and Refreshment Break**

CHALLENGES IN CLINICAL DEVELOPMENT

16:15 **Challenges in Clinical Development of Biosimilars**

- Common issues in the clinical development of biosimilars
- Ways to address the challenges
- Some case studies from the region

Dr Charu Manaktala, *Medical Director*, **Quintiles**, India

16:45 **Challenges and Obstacles for Clinical Trials in Biosimilars Development**

CLINICAL LEADERS' PANEL DISCUSSION

- Overcoming the challenges of immunogenicity
- Patient safety and trial design
- Demonstrating biosimilarity and characterisation
- Quality by Design and clinical protocol

Panelists:
Joan Shen, *CMO*, **Jiangsu Hengrui Medicine**, China
Mudgal Kothekar, *DGM Clinical Biosimilars*, **Biocon**, India
Weidong Jiang, *CSO & Vice President*, **Henlius Biopharmaceuticals**, USA

EXAMINING RISK AND OPPORTUNITIES IN THE EVOLVING BIOSIMILARS MARKET IN ASIA

17:30 **Partnering to Capture the Region's Biosimilars Opportunities**

KEYNOTE PANEL DISCUSSION

- How can sales figures grow significantly?
- Which domestic players are leaders today and can be partners for the future?
- What are MNCs considering when evaluating the biosimilar market in China and what are their entry strategies going forward?

Moderator:
George Shen, *Vice President, Sales, Marketing and Business Development*, **Biomabs**, China

Panelists:
Youling Wu, *CEO*, **Zhejiang Teruisi**, China
Tadashi Matsumoto, *President*, **Reqmed**, Japan
Wei-Kuang Chi, *Vice President*, **Development Center for Biotechnology**, Taiwan

18:15 **Speed Networking Session and Networking Cocktails**

VIP 1: **Rafael Mendoza**, *Senior Director, Established Products Commercial Lead for Emerging Asia*, **Pfizer**, Hong Kong

Exclusive to Registered Participants Only: Limited Spots Available!
Participants have the chance to spend two minutes getting to know the key experts in the Biopharma industry and more! Secure your place today with **elle.quan@ibcasia.com.sg**

8:55 **Chairman's Summary of Day One and Opening Remarks**
Jason Li, *Senior Director*, **Genor Biopharma**, China

STRATEGIES FOR COMMERCIALIZATION AND MARKET ACCESS

9:00 **Understanding Obstacles and Hurdles for Entering the Biosimilars Market & Potential Solutions**

PANEL DISCUSSION

- Risk and opportunities of the evolving market of biosimilars
- Existing barriers to entry for developing biosimilars
- Cost of development and the real cost figures
- Developing biobetters for differentiation

Panelists:
Khai Meng Ang, *Vice President Asia*, **Hospira**, China
Sachidananda Moorthy, *Vice President – Clinical Research, Medical & Regulatory Affairs*, **Avesthagen**, India
Jason Li, *Senior Director*, **Genor Biopharma**, China

10:00 **Morning Networking and Refreshment Break**

10:30 **Market Strategies for Biosimilars in Oncology**

KEYNOTE

- Overview of the global biologics market
- Drivers of success for the oncology biosimilars business
- Market dynamics and strategies to suitably address the challenges
- Key criteria to consider for success in biosimilar marketing

Sameer Agarwal, *Senior Vice President, Business Center Strategic Marketing, Business Unit Generic Drugs & Standard Solutions*, **Fresenius Kabi Deutschland GmbH**, Germany

LEVERAGING ON THE GROWING BIOMANUFACTURING CAPABILITIES IN ASIA TO OPTIMIZE QUALITY

11:00 **Optimising Media for Biosimilars Development**
Senior Executive, **BD Biosciences**

11:30 **Enhancing Quality Manufacturing for Biosimilars**

PANEL DISCUSSION

- Selection of cell line and optimization of cell culture media
- Achieving scale up and addressing the accompanying challenges
- Success and sustainability of biosimilars manufacturing
- Bringing manufacturing technologies and standards to the same level as global players

Panelists:
Jianguo Yang, *Principal Scientist*, **Sanofi Genzyme**, USA
David Zhao, *SVP & CTO*, **Wuhan YZY Biopharm**, China
Michael Yu, *Founder, President & CEO*, **Innovent Biologics**, China

12:15 **Networking Lunch and VIP Tables**
If you would like to be seated on a table with our VIP guests in an exclusive lunch setting, please register your interest with **elle.quan@ibcasia.com.sg**. Limited seats are available!

PARTNERSHIPS & COLLABORATION

13:30 **Exploring Unique Alliances & Partnership Models to Optimize Biosimilars Development and Commercialization**

PANEL DISCUSSION

- Exploiting partnership models that align capabilities and business objectives
- Update on the key public collaborations to date
- Strengthening portfolio through licensing
- Commercial cooperation with biosimilar manufacturers

Moderator:
Yariv Hefez, *Vice President Business Development, Portfolio Management, Strategy and Partnering, Biosimilars*, **Merck Serono**, Switzerland

Panelists:
Fei Jiang, *Director, Business Development*, **3S Bio**, China

14:15 **What can Asia Learn from Global Biosimilars Development and Litigation?**

LEGAL AND IP LEADERS' PANEL

- Common legal and IP disputes in biosimilars
- Update on global biosimilars litigation
- Coordinating litigation strategies and positions in a global marketplace
- Defenses and strategies used in global biosimilars litigation
- Preparing for biosimilars patent litigation

Panelists:
Li Cai, *Regional R&D Counsel*, **Pfizer**, China
Viren Mahurkar, *Managing Director*, **HitchenRock Advisors**, Singapore
Vivek Mittal, *Head-Legal*, **Lupin**, India

15:00 **Afternoon Networking and Refreshment Break**

IS IT THE END OF THE BIOSIMILARS GOLD RUSH? A LOOK AT THE VALUE OF BIOSIMILARS INVESTMENTS

15:30 **Direction of the Industry's Fascination with Biosimilars**

KEYNOTE PANEL DISCUSSION

- Successful launches of biosimilars globally
- What are the actual costs of approvals compared to expected profits?
- Predicting market erosion and profit margins
- Assessing the promise and potential of Biosimilars
- Payers, physicians and patients: how do they see biosimilars?

Moderator:
Lawrence Wang, *Managing Director*, **Primavera Capital**, Hong Kong

Panelists:
James Huang, *Partner*, **KPCB**, China
Michael Choy, *Partner*, **BCG**, China

ROUND TABLE DISCUSSION

16:15 **Roundtable Discussions**

1. **Successful Commercialisation in Asia**
   Facilitator: **Salman Bokhari**, *Managing Director*, **Sidrapex**, Singapore
2. **mABs**
   Facilitator: **Li-Chung Huang**, *Chief Quality Officer*, **Henlius Biopharmacuetical**, USA
3. **Biosimilars in Oncology**

17:15 **Chairperson's Summary of the Day & End of Conference**

"Excellent conference."
~ Hefez, Merck Serono SA

"I improved my understanding of biosimilars development and gained real insights."
~ Fujishiro, Daiichi Sankyo

"Experienced people, good content."
~ Chan, Boehringer Ingelheim China

5TH ANNUAL BIOSIMILARS ASIA

WORKSHOPS

Pre-Conference Special Focus Day • 20 May 2014
CLINICAL DEVELOPMENT FOR BIOSIMILARS

8:30 **Registration**

9:00 **Chairman's Welcome and Opening Remarks**
Melvin Toh, *VP Development*, **CK Life Sciences**, Hong Kong

9:10 **Session 1: Panel Discussion – Strategies to Improve Sponsor, CRO, and Site Collaborations**
- Overview of latest trends in clinical research
- Effective biosimilars clinical study designs for Asia
- Identifying the role of each stakeholder
- Cultural considerations for successful partnering

Joan Shen, *CMO*, **Jiangsu Hengrui Medicine**, China

10:40 **Morning Networking and Refreshment Break**

11:10 **Session 2: Effective Clinical Research Project Management**
- Challenges in Good Clinical Practice (GCP) implementation
- Understanding the peculiarities of the region
- Establishing and managing timelines
- GCP best practices and Pharmacovigilance

Mudgal Kothekar, *DGM Clinical Biosimilars*, **Biocon**, India

12:40 **Networking Lunch**

14:00 **Session 3: Panel Discussion – Ensuring Patient Safety and Proving Efficacy of Biosimilars**
- Key regulatory considerations
- Demonstrating interchangeability and efficacy
- Promoting safety of biosimilars
- Role of pharmacology

15:30 **Afternoon Networking and Refreshment Break**

16:00 **Session 4: Regional Challenges in Patient Recruitment and Retention**
- Addressing the 'weak link' in clinical research
- Patient-centric approaches to increase patient pool
- Social media and physician engagement to improve patient recruitment and retention
- Enhancing site capabilities to improve the patient experience

Andrea Laslop, *Head of Scientific Office, Austrian Agency for Food & Health Safety, Austrian Member*, **European Medicines Agency**

17:30 **End of Pre-Conference Special focus Day**

Post-Conference Workshop A • 23 May 2014 • 9:00am – 12:30pm
CHALLENGES IN DEMONSTRATING BIOSIMILARITY AND INTERCHANGEABILITY OF BIOSIMILAR PRODUCTS

The market of biologics is growing at nearly twice the rate of pharma as a whole. The expiration of patents and other intellectual property rights for originator biologicals over the next decade opens up opportunities for biosimilars to enter the market and increase industry competition. In order to be cost effective a biosimilar product needs access to global markets based on a single development programme that meets the requirement of regulators internationally. Despite increasing alignment in the regulatory requirements for biosimilars between EMA, FDA, WHO and other jurisdiction, there are still many scientific and practical challenges for demonstrating biosimilarity and interchangeability including scientific factors, drug interchangeability and statistical considerations.

Key Workshop Topics:
- Scientific factors
- How similar is similar?
- Study design and choice of endpoints
- Interchangeability designs
- Safety assessment
- Statistical considerations
- Criteria for biosimilarity
- Biosimilarity versus non-inferiority
- Current status with substitution and Interchangeability

About the Workshop Leader:

Rodeina Challand, *Executive Director, Biosimilars Development*, **PRA**

Rodeina has 25 years experience in Healthcare, Science Research and Pharmaceutical industry, across a wide range of roles including Clinical Development Strategies for Biosimilars in Hospira Inc and Head of Clinical Operations in the EU. After graduating from London University in Biochemistry, she worked in Cancer Research and then joined the Pharmaceutical Industry. For over 10 years she directed the conduct of phase I to phase IV clinical trials including large pivotal multinational, multicenter trials, most of which have led to Marketing Authorisation. She was the lead in the development of Hospira's first Biosimilar, Hospira GCSF, from lab to clinic. Rodeina was also a member of the European Generic Association Biopharmaceutical Group (EBG) who played a key role in the development of the EMA Biosimilar Guidelines since the start in 2004.

Post-Conference Workshop B • 23 May 2014 • 1:30pm – 5:00pm
SUCCESSFULLY BRINGING BIOSIMILARS TO MARKET

After a relatively slow start, a number of promising biosimilars are expected to be commercialized in the coming 3-5 years. With patents set to expire on leading biologics, and payors pushing for lower prices to manage increasing healthcare costs, the demand for biosimilars is expected to grow.

However, Some Key Questions Remain:
- How big is the commercial opportunity for biosimilars and how best can such an opportunity be quantified?
- How will regulators assess biosimilars?
- What is the optimal go-to-market model for biosimilars?
- How will biosimilars price themselves?
- How will originators respond to the biosimilars threat?
- How will prescribers assess interchangeability and how will patients view substitution?

In this workshop, the following areas will be covered:
- Suggested ways to analyze and prioritize market potential without relying only on IMS data
- Selected risk minimization approaches with creative entry strategies.
- Strategies to effectively manage unforeseen change
- Strategic decisions in launching a new product

Workshop Programme
- Creating a Market Attractiveness Grid
- Allocating resources – short case study
- Launching a new brand – case study
- Increasing sales and also profitability
- Suggested Partnership Models
- Meeting and managing expectations

About the Workshop Leader:

Salman Bokhari, *Managing Director*, **Sidrapex**, Singapore

Salman Bokhari has almost 35 years of successful international business and management experience with an extensive background in Asian and Middle Eastern contexts. He has an established record of delivering competitive advantage and market share gains for internationally-driven companies in startup, turnaround, and growth environments. He has a proven expertise in formulating lean operations and executing market-winning strategies. Salman is an entrepreneurial leader who drives above-average growth and profitability by repositioning businesses, establishing strategic alliances and licensing agreements, building high performance teams, and reorganizing distribution channels.

Salman led the setting up of Lundbeck's country operations in Asia, and taking the lead antidepressant compound to leadership position in multiple markets. Prior to Lundbeck, Salman headed New Business Development in the Asia-Pacific Region for Schwarz Pharma, with the main focus on North Asia & China. He was with Ciba-Geigy, later Novartis, in various headquarters and country general management roles, in Switzerland, the Middle East & Asia.
Currently, Salman is the Managing Director of Sidrapex Pte Ltd, a life sciences strategy consulting firm he founded in Singapore. During the last four years he has been involved in helping set up the regional and global operations of niche generic and specialty pharmaceutical companies. He also contributes regularly with write-ups to SCRIP Asia 100 and is a speaker at regional conferences.

Salman has a BA (Honours) from the University of East Anglia in the UK and an MBA from the Management Centre, in Bradford, UK. He has also attended the Senior Executive Program at Columbia University, New York, USA. He holds a Swiss passport.

5TH ANNUAL

BIOSIMILARS ASIA

20 — 23 May 2014

Grand Hyatt Shanghai, China

Part of BIOPHARMA DEVELOPMENT & PRODUCTION WEEK

Asia's Longest Running & Biggest Biosimilars Event

亚洲最大、运营最久的生物仿制药活动

China remains an attractive destination for MNCs and regional pharma players for biosimilars development. Risks are reduced through strategic alliances and partnerships with local Chinese manufacturers. While partnering with local China companies can bring economies of scale, market knowledge and better networks, there are also learning opportunities from partnering with MNCs in terms of quality assurance, improved R&D processes and technology transfer.

IBC's **5th Annual Biosimilars Asia** brings together senior level biosimilar development, manufacturing and commercialization decision makers from Asia and globally to provide an unrivalled platform to talk about the most pressing strategic challenges in partnerships and in the development of biosimilars.

Top 5 Reasons to Attend

- Learn from in-depth case studies on strategic partnering and effective collaboration with Asian companies
- Explore new business opportunities and strategies to reach the biosimilars market in the region
- Gain insights into the regulatory landscape for biosimilars in China, India, Korea, Taiwan and more
- Obtain strategies for partnering in specific therapeutic areas and geographical areas
- Gather the latest market intelligence and analysis and identify new trends and opportunities in Biosimilars R&D, contract manufacturing and commercialization in Asia

Who Should Attend:



BY COUNTRY
- North Asia **65%**
- USA **12%**
- Europe **8%**
- Southeast Asia **5%**
- India **5%**
- Rest of the World **5%**



BY INDUSTRY:
- Innovator **35%**
- Generics Companies **17%**
- Biotech **15%**
- CRAMS/CMOS **10%**
- Legal **8%**
- CROS **5%**
- Solution Providers **5%**
- Academics **5%**

About the BDP Week

The Biopharma Development & Production Week is the leading industry platform for pharma, biotech, CMOs, CROs, research institutes, investors and industry stakeholders to meet, network and discuss current industry trends, establish business partnerships and be updated on investment opportunities in China and surrounding Asia.
Visit **www.biopharmaproduction.com** for more information.

Co-Located with:

CELL LINE DEVELOPMENT & ENGINEERING ASIA
www.celllineasia.com

BIO MANUFACTURING
www.biomanufacturing-asia.com

Hear Some of the Rave Reviews from Attendees at Last Year's Event!

"Good updates on the biosimilars market and regulations"
~ Esteve Quinica

"Great insight into global thought processes on biosimilar development"
~ Avesthagen

"I walked away with an indepth understanding of trends in biologies/biosimilars, regulatory hurdles and market access"
~ Besins

SPONSORSHIP OPPORTUNITIES

Raise awareness for your services available to Asian pharmaceuticals!

- Do you find difficulty in reaching senior decision makers and successfully stimulating interest for your services?
- Are you trying to raise awareness of the value of your company's expertise and services?
- Or are you finding it difficult to differentiate your company from competition?

Perhaps what you need is a branding opportunity at this event! Increase your reach through our extensive marketing campaign, targeted at your qualified business audience.

For information about placing your brand & profile top-of-mind to key buyers, contact Yvonne Leong, Business Development Manager on Tel: **+65 6508 2489** or Email: **yvonne.leong@ibcasia.com.sg**

Past attending companies include:

Zhejiang Teruisi Pharmaceutical • Teva • Pfizer • Celltrion • Sandoz • F Hoffmann-La Roche • Dr Reddys • Samsung • Daiichi Sankyo • Biocon • Merck Serono • Esteve Quimica S.A. • Hospira • Genzyme • Wockhardt • Merck Sharp & Dohme • Cipla • Development Center for Biotechnology • Hanwha Chemical • Shanghai Roche Pharmaceuticals • TTY Biopharm • Besins Healthcare Shanghai • Intas Biopharmaceuticals • Simcere Pharmaceutical • R&D Center of Chinese Academy of Medical Sciences • U.S. Department of Defense • Abbott Laboratories • Boehringer Ingelheim Shanghai • Xian-Janssen Pharmaceutical • European Generic Medicines Association (EGA) • Bayer Healthcare • Avesthagen • Shin Nippon Biomedical Laboratories • Shanghai Hengrui Pharmaceutical • GlaxoSmithKline

REGISTER TODAY! Email: elizabeth.bernos@ibcasia.com.sg Tel no. +65 65082490 Fax no. +6565082406

If undelivered, please return to:

IBC ASIA (S) PTE LTD
COMPANY NO: 200108203N
an Informa business

111 Somerset Road,
TripleOne Somerset #10-06, Singapore 238164
Tel: +65 6508 2400 Fax: +65 6508 2408

SAVE WITH THE EARLY BIRD & SPECIAL RATES!

5th Biosimilars Asia

ENJOY SUBSTANTIAL SAVINGS WITH OUR MULTIPLE BOOKING DISCOUNT!

EASY WAYS TO REGISTER

Email your registration form to: elizabeth.bernos@ibcasia.com.sg

Call Eliz @:
Tel no. +65 65082490

This label contains your priority booking code. To expedite registration, please do not remove label. If you have already received a copy of this brochure, we apologise. For reasons of confidentiality, your full particulars were not available to IBC Asia (S) Pte Ltd for deduplication prior to mail drop.

RESERVE YOUR PLACE TODAY!

❑ Yes! I/We will attend the **5th Biosimilars Asia**
20 – 23 May 2014, Grand Hyatt Shanghai, China

❑ I would like to purchase the conference presentations at SGD1000 + GST (SGD1070) per log in.

FEE PER DELEGATE International Companies	Early Bird Rate Register & pay on or before 14 Mar 2014	Special Rate Register & pay before 11 Apr 2014	Normal Rate Register & pay after 11 Apr 2014	Group Rate (3 or more delegates)
❑ **4 Day:** Conf + Pre and Post-Workshops	USD 2,695	USD 2,895	USD 2,995	USD 2,495
❑ **3.5 Day:** Conf+Pre-Workshop+Post-Workshop ❑ A or ❑ B	USD 2,495	USD 2,695	USD 2,795	USD 2,295
❑ **3 Day:** Conf + ❑ Pre-Workshop or ❑ 2 Post-Workshops	USD 2,295	USD 2,495	USD 2,595	USD 2,095
❑ **2.5 Day:** Conf + Post Workshop ❑ A or ❑ B	USD 1,995	USD 2,195	USD 2,295	USD 1,795
❑ **2 Day:** Conference only	USD 1,695	USD 1,895	USD 1,995	USD 1,495
China Domestic Companies				
❑ **4 Day:** Conf + Pre and Post-Workshops	CNY 6,500	CNY 7,500	CNY 8,000	CNY 6,000
❑ **3.5 Day:** Conf+Pre-Workshop+Post-Workshop ❑ A or ❑ B	CNY 6,000	CNY 7,000	CNY 7,500	CNY 5,500
❑ **3 Day:** Conf + ❑ Pre-Workshop or ❑ 2 Post-Workshops	CNY 5,500	CNY 6,500	CNY 7,000	CNY 5,000
❑ **2.5 Day:** Conf + Post Workshop ❑ A or ❑ B	CNY 5,000	CNY 6,000	CNY 6,500	CNY 4,500
❑ **2 Day:** Conference only	CNY 4,500	CNY 5,500	CNY 6,000	CNY 4,000

International Companies: Companies whose global headquarters are located outside mainland China. China Domestic Companies: Companies whose global headquarters are located within mainland China. Academia/Government: 40% off the normal rate

GROUP BONUS: REGISTER 3 DELEGATES FROM THE SAME COMPANY AND THE 4TH ATTENDS FOR FREE!

- Multiple Bookings Discount pricing is applicable to groups of 3 or more delegates from the same organisation registering for the same event, at the same time. Fee stated is the discounted price PER DELEGATE. Only one discount applies; either the early bird rate OR special rate OR group rate.
- All fees stated include luncheons, refreshments and complete set of documentation. It does not include the cost of accommodation and travel.
- Registration fees are subject to the prevailing government tax

Delegate 1 Details

Name: Dr/Mr/Ms
Job Title:
Department
Tel:
Mobile No.:
Email:

Delegate 2 Details

Name: Dr/Mr/Ms
Job Title:
Department
Tel:
Mobile No.:
Email:

Delegate 3 Details

Name: Dr/Mr/Ms
Job Title:
Department
Tel:
Mobile No.:
Email:

GROUP DISCOUNT

Delegate 4 Details

Name: Dr/Mr/Ms
Job Title:
Department
Tel:
Mobile No.:
Email:

FREE

Please photocopy for additional delegates

Who is Head of your Department?

Who is Head of Training?

Company Information

Company Name: | Main Business/Activity:

Address: | Postal Code:

Payment Method (Please tick:)
❑ I enclose my bankers draft / cheque payable to IBC Asia (S) Pte Ltd
❑ I am paying by bank transfer (copy attached)
❑ Payment by Credit Card. (AMEX, VISA or MasterCard accepted)

CREDIT CARD PAYMENTS
The best way to pay by credit card is through our secure on-line registration process, simply log on to the website at **www.biosimilarsasia.com** and click "Register On-line". If you would prefer to pay over the phone please complete the contact name and details and our Customer Services Team will call within 24 hours to take payment. As we treat your credit card information in the strictest confidence, please do not send payment details by email.

Credit card contact: _____ Department: _____
Direct phone number: _____ Email: _____

P46236 ts

HOTEL INFORMATION

Grand Hyatt Shanghai, China
Jin Mao Tower, 88 Century Boulevard
Pudong, Shanghai 200121
Tel: +86 21 5049 1234 | Fax: +86 21 5049 8381
Contact Person: Judy Xu
Email: judy.xu@hyatt.com

PAYMENT TERMS

Payment must be received 10 business days prior to the event. To take advantage of discounts with an expiry cut-off date, registration and payment must be received by the cut-off date. All payments should be made in US or CNY dollars.

- **Payments by US$ bank draft or cheque should be made in favour of "IBC Asia (S) Pte Ltd" and mailed to:**
  IBC Asia (S) Pte Ltd
  c/o Informa Regional Business Services
  111 Somerset Road, TripleOne Somerset #10-06,
  Singapore 238164
  Attn: The Accounts Receivable Team
- **Payment by telegraphic transfer in US$ must be made to:**
  IBC Asia (S) Pte Ltd
  A/C No.: 260-457866-178 (USD)
  The Hongkong and Shanghai Banking Corporation Limited,
  21 Collyer Quay, HSBC Building, Singapore 049320
  Bank Swift Code: HSBCSGSG
  Bank Code: 7232
- **Payment by telegraphic transfer in CNY must be made to:**
  A/C Name: 艾毕思会务服务（上海）有限公司 IBC Conferences and Event Management Services (Shanghai) Co., Ltd.
  A/C No.: 720-031103-001
  Beneficiary Bank: 汇丰银行（中国）有限公司上海分行 HSBC Bank (China) Company Limited
  Bank Address: No. 1000 Lujiazui Rind Road, Pudong, Shanghai 200120, P.R. China
- **Payment by credit card in US$ (AMEX, VISA or MasterCard)**
  The best way to pay by credit card is through our secure portal built into the website. To pay by phone please indicate the contact name and details below and our Customer Services Team will call within 24 hours to take payment. Please do not send credit card information by email.

CANCELLATION / SUBSTITUTION

Should you be unable to attend, a substitute delegate is welcome at no extra charge. Cancellations must be received in writing at least 10 business days before the start of the event, to receive a refund less 10% processing fee per registration. The company regrets that no refund will be made available for cancellation notifications received less than 10 business days before the event.

IMPORTANT NOTE

Please quote the name of the delegate, event title and invoice number on the advice when remitting payment. Bank charges are to be deducted from participating organisations own accounts. Please fax your payment details (copy of remittance advice, cheque or draft to +65 6508 2407).

Attendance will only be permitted upon receipt of full payment. Participants wishing to register at the door are responsible to ensure all details are as published. IBC assumes no further liability or obligation, beyond the refund of the paid registration fee, in the event of postponement or cancellation by IBC.

DATA PROTECTION

The personal information entered during your registration/order, or provided by you, will be held on a database and may be shared with companies in the Informa Group in the UK and internationally. Occasionally, your details may be obtained from or shared with external companies who wish to communicate with you offers related to your business activities. If you do not wish your details to be used for this purpose, please contact our Database Department at Email: database@ibcasia.com.sg, Tel: +65 6508 2400 or Fax: +65 6508 2408.

REG NO. 200108203N